renal inflammation

Deoxycorticosterone acetate (DOCA) is a steroid hormone produced by the adrenal glands, possessing mineralocorticoid activity and serving as a precursor to aldosterone. As an agonist of the mineralocorticoid receptor, DOCA can induce severe kidney damage, including inflammation, fibrosis, glomerular injury, and proteinuria. It is commonly used to establish animal models of chronic kidney injury and hypertension.

CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia.

4-Hydroxychalcone (P-Cinnamoylphenol) attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice.

Methylguanidine (MG) is a guanidine compound deriving from protein catabolism. It is also a product of putrefaction. Methylguanidine is a suspected uraemic toxin that accumulates in renal failure, however it also exhibits anti-inflammatory effects. Methyl

PFI-2 is an effective, specific and cell-active lysine methyltransferase SETD7 inhibitor (Ki/IC50: 0.33/2 nM), 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.

Ferroptosis-IN-12 (Cpd-A1) is an inhibitor of ferroptosis. It effectively suppresses ferroptosis in mouse renal tubular epithelial cells (mTECs) treated with Erastin and improves renal function in dose-dependent manners in mouse models of acute kidney injury (AKI) induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). This compound also reduces renal tubular damage and eliminates inflammation. Exhibiting good plasma stability and high distribution in renal tissues during pharmacokinetic studies in mice, Ferroptosis-IN-12 shows promising potential for research in the field of AKI.

PROTACSTING degrader-4 is a covalent STINGPROTAC degrader free of nitro groups, exhibiting a DC50 of 3.23 μM. It effectively inhibits STING and its downstream signaling pathways, including p-TBK1 and p-NF-κB (p-P65), as well as immune-inflammatory cytokines. Additionally, PROTACSTING degrader-4 mitigates renal and blood inflammation in mouse models of Cisplatin-induced acute kidney injury (AKI).

Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor with an IC50 of less than 10 nM and demonstrates high selectivity over MMP-1, -2, -3, -7, -9, -10, and -14. It significantly reduces lung fibrosis in a mouse model of bleomycin-induced unilateral pulmonary fibrosis and effectively alleviates kidney damage, interstitial inflammation, or fibrosis in a unilateral ureteral obstruction renal fibrosis model. Linvemastat is suitable for research into inflammatory diseases such as idiopathic pulmonary fibrosis (IPF), inflammatory bowel disease (IBD), and asthma.

Bradykinin (acetate) is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions. Enzymatically produced from kallidin in the blood, it is a powerful vasodilator that causes smooth muscle contraction, and may mediate inflammation. It has a role as a human blood serum metabolite and a vasodilator agent. It is a tautomer of a bradykinin(2+).

PFI-2 hydrochloride ((R)-PFI-2 hydrochloride) is a potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 (IC50: 2 nM), 500 fold active than (S)-PFI-2.

Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes signals by inducing autophagy. Evogliptin can be used to study type 2 diabetes, chronic liver inflammation, osteoporosis and renal impairment.

BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].

Anti-Mouse CD11b Antibody (M1/70) is a rat-derived antibody targeting mouse CD11b that can significantly inhibit the adhesion between dendritic cells (DCs) and platelets, kill ovarian cancer cells and suppress their migration, as well as alleviate renal fibrosis and inflammation. This antibody can be used in the research of inflammatory diseases and cancers, such as ischemia-reperfusion injury (IRI), thrombotic inflammatory diseases and ovarian cancer .

Cirsimaritin exhibits antibacterial, anti-inflammation, anti-tumor, antioxidant properties and renal protection. Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors.